Devices Containing Ancillary Medicines Likely To Need ‘Near Full Review’ Under MDR
Executive Summary
Latest EU guidance highlights the challenges ahead for class III, high-risk, device/drug combinations when preparing for compliance under the tougher requirements of the MDR.